Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance

29 Dec 2023

Abstract excerpt

The concept of post-therapy metastatic spread, cancer repopulation and acquired tumor cell resistance (M-CRAC) rationalizes tumor progression because of tumor cell heterogeneity arising from post-therapy genetic damage and subsequent tissue repair mechanisms. Therapeutic strategies designed to specifically address M-CRAC involve tissue editing approaches, such as low-dose metronomic chemotherapy and the use of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Health, Environment, Cognitive Aging
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38201607
DOI: 10.3390/cancers16010180

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell ResistancePMID 38201607Read ↗

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy ResistanceSemantic proximity Read ↗

Comprehensive genome editing confers ‘off-the-shelf’ CAR-T cells superior efficacy against solid tumorsSemantic proximity Read ↗

Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncologySemantic proximity Read ↗

SnapShot: Cancer immunoediting.Semantic proximity Read ↗

Genome Editing in Engineered T Cells for Cancer ImmunotherapySemantic proximity Read ↗

Distinct Spatial Programs of Response versus Resistance in Non-Small Cell Lung Cancer after Neoadjuvant ChemoimmunotherapySemantic proximity Read ↗

Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trialsSemantic proximity Read ↗

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancySemantic proximity Read ↗

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.Semantic proximity Read ↗

Reprogramming the tumor microenvironment by genome editing for precision cancer therapySemantic proximity Read ↗

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphomaSemantic proximity Read ↗

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.